In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on ImmunoPrecise Antibodies (IPA – Research Report), with a price target of $9.00. The company’s shares opened today at $3.37.
According to TipRanks, Ramakanth is an analyst with an average return of -18.6% and a 25.15% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Asensus Surgical, ImmunoGen, and MiMedx Group.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ImmunoPrecise Antibodies with a $9.00 average price target.
See the top stocks recommended by analysts >>
IPA market cap is currently $93.51M and has a P/E ratio of -3.98.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IPA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ImmunoPrecise Antibodies Ltd. engages in the provision of integrated antibody solutions. It services include human monoclonals, hybridoma development, rabbit monoclonals, b-cell select, phage display, cryostorage, hybridoma sequencing, antibody generation, anti-body purification, polyclonal production, and peptide production. The company was founded by Robert Beecroft in 1989 and is headquartered in Victoria, Canada.
